Posts With Tag Imfinzi

AstraZeneca's Imfinzi receives EMA approval recommendation for NSCLC. AEGEAN trial shows significant recurrence reduction, enhancing patient outcomes and market potential.

AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.